# EDGAR Filing Document

**Accession Number:** 0001690585
**File Stem:** 0001690585-26-000007
**Filing Date:** 2026-3
**Character Count:** 26439
**Document Hash:** ac798c3d99828ee5914538fa7e7fa705
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001690585-26-000007.hdr.sgml**: 20260309

**ACCESSION NUMBER**: 0001690585-26-000007

**CONFORMED SUBMISSION TYPE**: S-8

**PUBLIC DOCUMENT COUNT**: 16

**FILED AS OF DATE**: 20260309

**DATE AS OF CHANGE**: 20260309

**EFFECTIVENESS DATE**: 20260309

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Dianthus Therapeutics, Inc. /DE/
- **CENTRAL INDEX KEY:** 0001690585
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-294134
- **FILM NUMBER:** 26733363

**BUSINESS ADDRESS:**
- **STREET 1:** 7 TIMES SQUARE
- **STREET 2:** 43RD FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10036
- **BUSINESS PHONE:** 929-999-4055

**MAIL ADDRESS:**
- **STREET 1:** 7 TIMES SQUARE
- **STREET 2:** 43RD FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10036

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Magenta Therapeutics, Inc.
- **DATE OF NAME CHANGE:** 20161121

**As filed with the Securities and Exchange Commission on March 9, 2026**

**Registration No. 333-** 

---

| | | |
|:---|:---|:---|
| **UNITED STATES**<br>**SECURITIES AND EXCHANGE COMMISSION**<br>**WASHINGTON, DC 20549** | **UNITED STATES**<br>**SECURITIES AND EXCHANGE COMMISSION**<br>**WASHINGTON, DC 20549** | **UNITED STATES**<br>**SECURITIES AND EXCHANGE COMMISSION**<br>**WASHINGTON, DC 20549** |
| **FORM S-8**<br>**REGISTRATION STATEMENT**<br>***UNDER***<br>***THE SECURITIES ACT OF 1933*** | **FORM S-8**<br>**REGISTRATION STATEMENT**<br>***UNDER***<br>***THE SECURITIES ACT OF 1933*** | **FORM S-8**<br>**REGISTRATION STATEMENT**<br>***UNDER***<br>***THE SECURITIES ACT OF 1933*** |
| **Dianthus Therapeutics, Inc.** | **Dianthus Therapeutics, Inc.** | **Dianthus Therapeutics, Inc.** |
| **(Exact name of registrant as specified in its charter)** | **(Exact name of registrant as specified in its charter)** | **(Exact name of registrant as specified in its charter)** |
| **Delaware** |  | **81-0724163** |
| **(State or Other Jurisdiction of**<br>**Incorporation or Organization** |  | **(I.R.S. Employer**<br>**Identification No.)** |
| **7 Times Square, 43rd Floor**<br>**New York, NY 10036** | **7 Times Square, 43rd Floor**<br>**New York, NY 10036** | **7 Times Square, 43rd Floor**<br>**New York, NY 10036** |
| **(Address of Principal Executive Offices, Zip Code)** | **(Address of Principal Executive Offices, Zip Code)** | **(Address of Principal Executive Offices, Zip Code)** |
| **Second Amended and Restated Dianthus Therapeutics, Inc. Stock Option and Incentive Plan** | **Second Amended and Restated Dianthus Therapeutics, Inc. Stock Option and Incentive Plan** | **Second Amended and Restated Dianthus Therapeutics, Inc. Stock Option and Incentive Plan** |
| **Dianthus Therapeutics, Inc. 2019 Employee Stock Purchase Plan, as amended** | **Dianthus Therapeutics, Inc. 2019 Employee Stock Purchase Plan, as amended** | **Dianthus Therapeutics, Inc. 2019 Employee Stock Purchase Plan, as amended** |
| **Dianthus Therapeutics, Inc. Equity Inducement Plan** | **Dianthus Therapeutics, Inc. Equity Inducement Plan** | **Dianthus Therapeutics, Inc. Equity Inducement Plan** |
|  | **(Full title of the plan)** |  |
| **Adam M. Veness, Esq.**<br>**Senior Vice President, General Counsel and Secretary**<br>**Dianthus Therapeutics, Inc.**<br>**7 Times Square, 43rd Floor**<br>**New York, NY 10036**<br>**(929) 999-4055** | **Adam M. Veness, Esq.**<br>**Senior Vice President, General Counsel and Secretary**<br>**Dianthus Therapeutics, Inc.**<br>**7 Times Square, 43rd Floor**<br>**New York, NY 10036**<br>**(929) 999-4055** | **Adam M. Veness, Esq.**<br>**Senior Vice President, General Counsel and Secretary**<br>**Dianthus Therapeutics, Inc.**<br>**7 Times Square, 43rd Floor**<br>**New York, NY 10036**<br>**(929) 999-4055** |
|  | ***Copies to:*** |  |
| **Ryan A. Murr, Esq.**<br>**Branden C. Berns, Esq.** <br>**Gibson, Dunn & Crutcher LLP**<br>**One Embarcadero Center, Suite 2600**<br>**San Francisco, CA 94111**<br>**Telephone: (415) 393-8200**<br>**Facsimile: (415) 393-8306** | **Ryan A. Murr, Esq.**<br>**Branden C. Berns, Esq.** <br>**Gibson, Dunn & Crutcher LLP**<br>**One Embarcadero Center, Suite 2600**<br>**San Francisco, CA 94111**<br>**Telephone: (415) 393-8200**<br>**Facsimile: (415) 393-8306** | **Ryan A. Murr, Esq.**<br>**Branden C. Berns, Esq.** <br>**Gibson, Dunn & Crutcher LLP**<br>**One Embarcadero Center, Suite 2600**<br>**San Francisco, CA 94111**<br>**Telephone: (415) 393-8200**<br>**Facsimile: (415) 393-8306** |
| Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer", "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act. | Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer", "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act. | Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer", "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act. |

---

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ☐ | Accelerated filer | ☐ |
| Non-accelerated filer | ☒ | Smaller reporting company | ☒ |
|  |  | Emerging growth company | ☐ |

---

<u>If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐</u>

------

**EXPLANATORY NOTE**

This Registration Statement on Form S-8 (this "***Registration Statement***") registers (i) 2,161,025 additional shares of common stock, $0.001 par value per share ("***Common Stock***"), of Dianthus Therapeutics, Inc. (the "***Registrant***") under the Second Amended and Restated Dianthus Therapeutics, Inc. Stock Option and Incentive Plan (the "***Incentive Plan***"), (ii) 62,500 additional shares of Common Stock under the Dianthus Therapeutics, Inc. 2019 Employee Stock Purchase Plan, as amended (the "***ESPP***"), and (iii) 600,000 additional shares under the Dianthus Therapeutics, Inc. Equity Inducement Plan (the "***Inducement Plan***"), which was approved by the Registrant's board of directors on December 17, 2025 to provide for the grant of additional inducement awards under the Inducement Plan in accordance with the requirement of Nasdaq Listing Rule 5635(c)(4).

The number of shares of Common Stock reserved and available for issuance under the Incentive Plan is subject to an automatic annual increase on each January 1 by an amount equal to the lesser of 5% of the number of shares of Common Stock issued and outstanding on the immediately preceding December 31 or such lesser number of shares of Common Stock as determined by the Administrator (as defined in the Incentive Plan). Accordingly, on January 1, 2026, the number of shares of Common Stock reserved and available for issuance under the Incentive Plan increased by 2,161,025 shares. The additional shares are of the same class as other securities relating to the Incentive Plan for which the Registrant's registration statement filed Form S-8 filed with the Securities and Exchange Commission (the "***SEC***") on March 11, 2025, August 8, 2024, March 21, 2024, October 4, 2023, March 8, 2022, March 3, 2021, March 3, 2020, March 19, 2019 and June 22, 2018 (Registration Nos. [<u>333-285709</u>](https://www.sec.gov/Archives/edgar/data/1690585/000095017025037136/dnth-form_s-8-2025.htm), [<u>333-281381</u>](https://www.sec.gov/Archives/edgar/data/1690585/000095017024094063/dnth-form_s-8-mid-2024.htm), [<u>333-278151</u>](https://www.sec.gov/Archives/edgar/data/1690585/000095017024034865/dnth-form_s-8-2024.htm), [<u>333-274865</u>](https://www.sec.gov/Archives/edgar/data/1690585/000119312523250784/d539790ds8.htm), [<u>333-263358</u>](https://www.sec.gov/Archives/edgar/data/1690585/000119312522068760/d298425ds8.htm), [<u>333-253815</u>](https://www.sec.gov/Archives/edgar/data/1690585/000119312521066715/d131920ds8.htm), [<u>333-236853</u>](https://www.sec.gov/Archives/edgar/data/1690585/000119312520059839/d872582ds8.htm), [<u>333-230387</u>](https://www.sec.gov/Archives/edgar/data/1690585/000119312519078954/d718678ds8.htm), and [<u>333-225838</u>](https://www.sec.gov/Archives/edgar/data/1690585/000119312518201118/d781480ds8.htm)), and which, together with all exhibits filed therewith or incorporated therein by reference, are hereby incorporated by reference pursuant to General Instruction E to Form S-8 and the shares of Common Stock registered hereunder with respect to the Incentive Plan are in addition to the shares of Common Stock registered on such registration statements.

The number of shares of Common Stock reserved and available for issuance under the ESPP is subject to an automatic annual increase on each January 1 by an amount equal to the least of (i) 1% of the number of shares of Common Stock issued and outstanding on the immediately preceding December 31, (ii) 62,500 shares of Common Stock or (iii) such number of shares of Common Stock as determined by the Administrator (as defined in the ESPP). Accordingly, on January 1, 2026, the number of shares of Common Stock reserved and available for issuance under the ESPP increased by 62,500. The additional shares are of the same class as other securities relating to the ESPP for which the Registrant's registration statement filed on Form S-8 filed with the SEC on March 11, 2025, March 21, 2024, March 8, 2022 and August 8, 2019 (Registration Nos. [<u>333-285709</u>](https://www.sec.gov/Archives/edgar/data/1690585/000095017025037136/dnth-form_s-8-2025.htm), [<u>333-278151</u>](https://www.sec.gov/Archives/edgar/data/1690585/000095017024034865/dnth-form_s-8-2024.htm), [<u>333-263358</u>](https://www.sec.gov/Archives/edgar/data/1690585/000119312522068760/d298425ds8.htm) and [<u>333-233125</u>](https://www.sec.gov/Archives/edgar/data/1690585/000119312519216838/d758408ds8.htm)), and which, together with all exhibits filed therewith or incorporated therein by reference, are hereby incorporated by reference pursuant to General Instruction E to Form S-8 and the shares of Common Stock registered hereunder with respect to the ESPP are in addition to the shares of Common Stock registered on such registration statements.

The number of shares of Common Stock reserved and available for issuance under the Inducement Plan was increased by an additional 600,000 shares pursuant to approval by the Registrant's Board of Directors on December 17, 2025. The additional shares are of the same class as other securities relating to the Inducement Plan for which the Registrant's registration statement filed on Form S-8 filed with the SEC on March 21, 2024 (Registration No. [<u>333-278151</u>](https://www.sec.gov/Archives/edgar/data/1690585/000095017024034865/dnth-form_s-8-2024.htm)), and which, together with all exhibits filed therewith or incorporated therein by reference, are hereby incorporated by reference pursuant to General Instruction E to Form S-8 and the shares of Common Stock registered hereunder with respect to the Inducement Plan are in addition to the shares of Common Stock registered on such registration statements.

**PART I**

**INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS**

**Item 1. Plan Information**

The documents containing the information specified in Part I of this Registration Statement will be delivered to employees as specified by Rule 428(b)(1) of the Securities Act of 1933, as amended (the "***Securities Act***"). In accordance with the instructions to Part I of Form S-8, such documents are not being filed with the SEC either as part of this Registration Statement or as prospectuses or prospectus supplements pursuant to Rule 424 of the Securities Act. Such documents and the documents incorporated by reference in this Registration Statement pursuant to Item 3 of Part II of Form S-8, taken together, constitute a prospectus that meets the requirements of Section 10(a) of the Securities Act.

**PART II**

**INFORMATION REQUIRED IN THE REGISTRATION STATEMENT**

**Item 8. Exhibits.**

------

---

| | |
|:---|:---|
| **Exhibit** <br>**Number** | **Description** |
| 4.1 | [<u>Fifth Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Registrant's Current Report on Form 8-K filed with the SEC on September 12, 2023)</u>](https://www.sec.gov/Archives/edgar/data/1690585/000119312523233448/d550960dex31.htm) |
| 4.2 | [<u>Third Amended and Restated By-laws (incorporated by reference to Exhibit 3.2 to the Registrant's Annual Report on Form 10-K filed with the SEC on March 21, 2024)</u>](https://www.sec.gov/Archives/edgar/data/1690585/000095017024034681/dnth-ex3_2.htm) |
| 5.1\* | [<u>Opinion of Gibson, Dunn & Crutcher LLP</u>](dnth-ex5_1.htm) |
| 23.1\* | [<u>Consent of Deloitte & Touche LLP, independent registered public accounting firm</u>](dnth-ex23_1.htm) |
| 23.2\* | [<u>Consent of Gibson, Dunn & Crutcher LLP (included in Exhibit 5.1)</u>](dnth-ex5_1.htm) |
| 24.1\* | [<u>Power of Attorney (included on the signature page to this Registration Statement)</u>](#power_of_attorney) |
| 99.1 | [<u>Second Amended and Restated Dianthus Therapeutics, Inc. Stock Option and Incentive Plan (incorporated by reference to Exhibit 10.1 to the Registrant's Current Report on Form 8-K filed with the SEC on May 28, 2024)</u>](https://www.sec.gov/Archives/edgar/data/1690585/000095017024065371/dnth-ex10_1.htm) |
| 99.2 | [<u>Dianthus Therapeutics, Inc. 2019 Employee Stock Purchase Plan, as amended (incorporated by reference to Exhibit 10.1 to the Registrant's Quarterly Report on Form 10-Q filed with the SEC on August 8, 2024)</u>](https://www.sec.gov/Archives/edgar/data/1690585/000095017024093948/dnth-ex10_1.htm) |
| 99.3 | [<u>Dianthus Therapeutics, Inc. Equity Inducement Plan (Amended and Restated on December 17, 2025)</u>](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000006/dnth-ex10_21.htm) |
| 107.1\* | [<u>Filing Fee Table</u>](dnth_exfilingfees.htm) |

---

\* Filed herewith.

------

**SIGNATURES**

Pursuant to the requirements of the Securities Act, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of New York, State of New York, on March 9, 2026.

---

| | |
|:---|:---|
| DIANTHUS THERAPEUTICS, INC. | DIANTHUS THERAPEUTICS, INC. |
| By: | /s/ Ryan Savitz |
| Name: | Ryan Savitz |
| Title: | Executive Vice President, Chief Financial Officer and Chief Business Officer |

---

**POWER OF ATTORNEY**

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints each of Marino Garcia, Ryan Savitz and Adam Veness and each of them acting individually, as his or her true and lawful attorneys-in-fact and agents, each with full power of substitution and resubstitution in each of them singly, for him or her and in his or her name, place and stead, and in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement, and to file the same, with all exhibits thereto and other documents in connection therewith, with the SEC, granting to the attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite or necessary to be done in or about the premises, as full to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that the attorneys-in-fact and agents or any of each of them or their substitutes may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act, this Registration Statement has been signed by the following persons in the capacities indicated on the dates indicated.

---

| | | |
|:---|:---|:---|
| **<u>Signature</u>** | **<u>Title</u>** | **<u>Date</u>** |
| /s/ Marino Garcia | President, Chief Executive Officer and Director | March 9, 2026 |
| Marino Garcia | *(Principal Executive Officer)* |  |
| /s/ Ryan Savitz | Executive Vice President, Chief Financial Officer and Chief Business Officer | March 9, 2026 |
| Ryan Savitz | *(Principal Financial Officer)* |  |
| /s/ Edward Carr | Chief Accounting Officer | March 9, 2026 |
| Edward Carr | *(Principal Accounting Officer)* |  |
| /s/ Alison Lawton | Director and Chair of the Board | March 9, 2026 |
| Alison Lawton |  |  |
| /s/ Sujay Kango | Director | March 9, 2026 |
| Sujay Kango |  |  |
| /s/ Anne McGeorge | Director | March 9, 2026 |
| Anne McGeorge |  |  |
| /s/ Steve Romano, M.D. | Director | March 9, 2026 |
| Steven Romano, M.D. |  |  |
| /s/ Simon Read, Ph.D. | Director | March 9, 2026 |
| Simon Read, Ph.D. |  |  |
| /s/ Paula Soteropoulos | Director | March 9, 2026 |
| Paula Soteropoulos |  |  |
| /s/ Jonathan Violin, Ph.D. | Director | March 9, 2026 |
| Jonathan Violin, Ph.D. |  |  |

---

------

## Exhibit 5.1

---

| | |
|:---|:---|
| ![img173831800_0.gif](img173831800_0.gif) | **Exhibit 5.1**<br>|

---

March 9, 2026

Dianthus Therapeutics, Inc.

7 Times Square, 43<sup>rd</sup>Floor

New York, NY 10036

Re: Dianthus Therapeutics, Inc.<br> Registration Statement on Form S-8

Ladies and Gentlemen:

We have examined the Registration Statement on Form S-8 (the "<u>Registration</u> <u>Statement</u>"), of Dianthus Therapeutics, Inc., a Delaware corporation (the "<u>Company</u>"), to be filed with the Securities and Exchange Commission (the "<u>Commission</u>") pursuant to the Securities Act of 1933, as amended (the "<u>Securities Act</u>"), in connection with the offering by the Company of (i) up to 2,161,025 shares of the Company's common stock, par value $0.001 per share (the "<u>Common Stock</u>"), issuable to eligible individuals under the Amended and Restated Dianthus Therapeutics, Inc. Stock Option and Incentive Plan (the "<u>Incentive Plan</u>"), (ii) up to 62,500 shares of Common Stock issuable to eligible individuals under the Dianthus Therapeutics, Inc. 2019 Employee Stock Purchase Plan (as amended, the "<u>ESPP</u>"), (iii) 600,000 shares of Common Stock issuable to eligible individuals under the Dianthus Therapeutics, Inc. Equity Inducement Plan (the "<u>Inducement Plan</u>" and together with the Incentive Plan and the ESPP, the "<u>Plans</u>").

In arriving at the opinions expressed below, we have examined originals, or copies certified or otherwise identified to our satisfaction as being true and complete copies of the originals, of the Plans and such other documents, corporate records, certificates of officers of the Company and of public officials and other instruments as we have deemed necessary or advisable to enable us to render these opinions. In our examination, we have assumed, without independent investigation, the genuineness of all signatures, the legal capacity and competency of all natural persons, the authenticity of all documents submitted to us as originals and the conformity to original documents of all documents submitted to us as copies. As to any facts material to these opinions, we have relied to the extent we deemed appropriate and without independent investigation upon statements and representations of officers and other representatives of the Company and others. We have also assumed without independent investigation that there are no agreements or understandings between or among the Company and any participants in the Plans that would expand, modify or otherwise affect the terms of the Plans or the respective rights or obligations of the participants thereunder.

Based upon the foregoing examination and in reliance thereon, and subject to the assumptions stated and in reliance on statements of fact contained in the documents that we have examined, we are of the opinion that the shares of Common Stock issuable under the Plans, when issued and sold in accordance with the terms of the Plans and against payment therefor, and when

**Gibson, Dunn & Crutcher LLP**<br>2001 Ross Avenue Suite 2100 \| Dallas, TX 75201-2923 \| T: 214.698.3100 \| F: 214.571.2900 \| gibsondunn.com

------

![img173831800_1.gif](img173831800_1.gif)

Dianthus Therapeutics, Inc.

March 9, 2026

the Registration Statement has become effective under the Securities Act, will be validly issued, fully paid and non-assessable.

We render no opinion herein as to matters involving the laws of any jurisdiction other than the Delaware General Corporation Law (the "<u>DGCL</u>"). We are not admitted to practice in the State of Delaware; however, we are generally familiar with the DGCL as currently in effect and have made such inquiries as we consider necessary to render the opinions above. This opinion is limited to the effect of the current state of the law of the DGCL and the facts as they currently exist. We assume no obligation to revise or supplement this opinion in the event of future changes in such law or the interpretations thereof or such facts.

We consent to the filing of this opinion as an exhibit to the Registration Statement, and we further consent to the use of our name in the Registration Statement and the prospectus that forms a part thereof. In giving these consents, we do not thereby admit that we are within the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations of the Commission promulgated thereunder.

Very truly yours,

/s/ Gibson, Dunn & Crutcher, LLP

Gibson, dunn & crutcher llp

------

## Exhibit 23.1

**Exhibit 23.1**

**CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM**

We consent to the incorporation by reference in this Registration Statement on Form S-8 of our report dated March 8, 2026 relating to the financial statements of Dianthus Therapeutics, Inc., appearing in the Annual Report on Form 10-K of Dianthus Therapeutics, Inc. for the year ended December 31, 2025.

/s/ Deloitte & Touche LLP

Morristown, New Jersey

March 8, 2026

------

## Ex-Filing

?xml version='1.0' encoding='ASCII'? EX-FILING FEES

Exhibit 107.1

**Calculation of** Filing Fee **Tables**

**Form** S-8

(Form Type)

Dianthus Therapeutics, Inc.

(Exact Name of Registrant as Specified in its Charter)

<u>Table 1: Newly Registered Securities</u>

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Security** <br>**Type** | **Security** <br>**Class** <br>**Title** | **Proposed**<br>**Maximum**<br>**Offering**<br>**Price Per**<br>**Unit** | **Maximum**<br>**Aggregate**<br>**Offering** <br>**Price** | **Fee** <br>**Rate** | **Amount of**<br>**Registration**<br>**Fee** |
| Equity | Common stock, $0.001 par value per share<br> Rule 457(a)<sup>(2)</sup><br>2161025<sup>(3)</sup> | $61.44 | $132773376.00 | $138.10 per $1,000,000 | $18336.00 |
| Equity | Common stock, $0.001 par value per share<br>Rule 457(a)<sup>(4)</sup><br>62500<sup>(5)</sup><br>| $52.22<br>| $3263750.00<br>| $138.10 per $1,000,000<br>| $450.72<br>|
| Equity | Common stock, $0.001 par value per share<br> Rule 457(a)<sup>(2)</sup><br>600000<sup>(6)</sup> | $61.44<br>| $36864000.00<br>| $138.10 per $1,000,000 | $5090.92<br>|
| **Total Offering Amounts** | **Total Offering Amounts** |  | $172901126.00 |  | $23877.64 |
| **Total Fee Offsets** | **Total Fee Offsets** |  |  |  |  |
| **Net Fee Due** | **Net Fee Due** |  |  |  | $23877.64 |

---

(1)Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the "***Securities Act***"), this Registration Statement on Form S-8 (this "***Registration Statement***") shall also cover any additional shares of common stock, par value $0.001 per share (the "***Common Stock***") of Dianthus Therapeutics, Inc. (the "***Registrant***") that become issuable under the Second Amended and Restated Dianthus Therapeutics, Inc. Stock Option and Incentive Plan (the "***Incentive Plan***"), the Dianthus Therapeutics, Inc. 2019 Employee Stock Purchase Plan, as amended (the "***ESPP***"), and the Dianthus Therapeutics, Inc. Equity Inducement Plan (the "***Inducement Plan***"), to prevent dilution in the event of stock splits, stock dividends or similar transactions.

(2)Estimated solely for the purpose of calculating the registration fee pursuant to Rules 457(c) and (h) of the Securities Act, and based on the average of the high and low sale prices of the Common Stock, as quoted on The Nasdaq Capital Market, on March 4, 2026.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3)Represents additional shares of Common Stock issuable under the Incentive Plan as a result of the automatic increase in shares reserved under the Incentive Plan on January 1, 2026 pursuant to the terms of the Incentive Plan.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(4)Estimated solely for the purpose of calculating the registration fee pursuant to Rules 457(c) and (h) of the Securities Act, and based on a 15% discount from the average of the high and low sale prices of the Common Stock, as quoted on The Nasdaq Capital Market, on March 4, 2026, such discount representing the discount offered pursuant to the ESPP.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(5)Represents additional shares of Common Stock issuable under the ESPP as a result of the automatic increase in shares reserved under the ESPP on January 1, 2026 pursuant to the terms of the ESPP.

(6)Represents an additional 600,000 shares of Common Stock issuable under the Inducement Plan as approved by the Registrant's Board of Directors on December 17, 2025.

------